Reserpine (N1867): Practical Lab Workflow

Reserpine is a bioactive natural product extracted from Rauvolfia plants and identified by CAS No. 50-55-5. The dossier describes methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate, with a molecular weight of 608.27 g/mol. In research records that use the indexed term 3,20-Yohimban-16-carboxylic acid, retain the CAS number, SKU, and lot information to prevent identity ambiguity.

Because no directly matched paper evidence is available for this product record, the recommendations below are limited to the product dossier and standard laboratory workflow controls. They are intended to support reproducible preparation rather than establish a dose, efficacy claim, or clinical outcome.

What This Product Solves

Many neuropharmacology experiments require a defined chemical input that can be weighed, dissolved, documented, and compared across assay runs. Reserpine N1867 addresses that reagent-control problem for workflows involving neurotransmitter depletion research, antihypertensive mechanism studies, hypertension-related laboratory models, and broader neuropharmacology research. Its high reported purity and HPLC/NMR characterization provide an incoming-material reference point, while its known water-insolubility makes solvent and dilution planning essential.

The practical challenge is not simply selecting a compound. It is maintaining consistent identity, stock preparation, vehicle exposure, storage history, and assay timing. Reserpine is insoluble in water and ethanol but is soluble in DMSO at concentrations of at least 13 mg/mL with gentle warming, according to the product dossier. Those properties make uncontrolled aqueous dilution a common source of precipitation and variable exposure. Freshly prepared samples are recommended because long-term storage of solutions can reduce experimental consistency.

For product-specific identity and handling information, consult the Reserpine product page and record SKU N1867 with the lot documentation in the laboratory notebook.

Protocol Parameters

• Assay: Identity and molarity calculation; Value: 608.27 g/mol; Applicability: all mass-to-molar concentration conversions; Rationale: use the dossier molecular weight rather than an unverified database value when preparing a stock; Evidence basis: product dossier.
• Assay: Solvent compatibility and stock preparation; Value: soluble in DMSO at concentrations ≥13 mg/mL with gentle warming, insoluble in water and ethanol; Applicability: concentrated-stock planning and dilution design; Rationale: a DMSO-first workflow reduces the risk of undissolved material during preparation; Evidence basis: product dossier.
• Assay: Incoming purity and identity review; Value: >98.8% purity confirmed by HPLC and NMR; Applicability: lot acceptance and experimental traceability; Rationale: retain the lot record and compare the received material with the stated characterization before use; Evidence basis: product dossier.
• Assay: Solid-state storage; Value: −20°C in a sealed, cool, dry container; Applicability: unopened and retained solid material; Rationale: limiting heat, moisture, and unnecessary vial opening supports compound integrity; Evidence basis: product dossier.
• Assay: Working-solution use; Value: prepare fresh and avoid long-term solution storage; Applicability: dosing or treatment solutions used in an active experiment; Rationale: freshly prepared samples are recommended for consistency, especially when the solution will be diluted into an aqueous assay matrix; Evidence basis: product dossier and workflow recommendation.

Workflow Setup and QC Checklist

1. Confirm material before opening

• Verify the product name, SKU N1867, CAS No. 50-55-5, lot identifier, and stated molecular weight against the receiving record.
• Inspect the package on arrival and document any evidence of leakage, damaged sealing, or unexpected material appearance. The dossier states that small-molecule shipments use blue ice; follow the receiving procedure established by the laboratory.
• Return the solid to −20°C storage in a sealed, cool, dry condition after inspection. Limit repeated warming and opening of the primary container.

2. Prepare a controlled stock

Plan the target molarity and final assay volume before weighing. Use the product molecular weight of 608.27 g/mol for the calculation, and document the actual mass, solvent volume, preparation date, operator, and lot. Begin with DMSO because the dossier identifies water and ethanol as unsuitable solvents for dissolution. Gentle warming may be used when needed, but avoid prolonged heating or leaving the container open.

After mixing, inspect the stock for visible particles, haze, or undissolved material. Do not assume that a clear appearance in DMSO guarantees stability after transfer into an aqueous assay medium. Add the stock gradually to the assay matrix with appropriate mixing and confirm that the intended final preparation remains free of visible precipitation.

3. Control the vehicle and exposure history

Include a vehicle control containing the same DMSO exposure as the treated condition. Keep the preparation sequence consistent between control and treatment groups. Prepare only the amount needed for the planned experiment, label the working solution clearly, and avoid retaining solutions for extended storage. If the assay requires repeated use, prepare separate fresh working solutions rather than repeatedly warming and cooling one container.

4. Document QC and experimental context

Use the HPLC/NMR purity statement as the incoming-material characterization supplied for the lot; do not describe it as a result generated by every experiment. Record whether the material was used for neurotransmitter depletion research, antihypertensive mechanism studies, or another defined neuropharmacology application. For endpoints involving monoamine measurements, document sample collection timing, matrix, analytical method, and any extraction or normalization steps separately from compound preparation.

The article Reserpine (SKU N1867): Technical Guide for Neuropharmacology Labs provides complementary context on reagent selection and reproducibility for depletion-oriented workflows. The Reserpine (N1867): Technical Workflow Guide for Lab Researchers extends this discussion with related handling and troubleshooting considerations.

Common Failure Modes and Fixes

Precipitation after aqueous dilution

Likely cause: the DMSO stock was added too quickly, the final solvent environment exceeded the compound's practical solubility, or mixing was inadequate. Fix: confirm complete dissolution in DMSO before transfer, add the stock gradually, mix immediately, and inspect the final preparation. If precipitation persists, do not treat the nominal concentration as the confirmed exposure; redesign the dilution sequence and revalidate the preparation.

Variable results between assay runs

Likely causes: different solution ages, inconsistent vehicle content, repeated freeze-thaw or warming cycles, inaccurate weighing, or undocumented lot changes. Fix: use fresh working solutions, match vehicle exposure, standardize the preparation order, and record mass, volume, lot, and preparation time for every run.

Unexpected loss of apparent activity

Likely causes: degraded or poorly stored solution, incomplete dissolution, adsorption or precipitation during dilution, or an assay-specific analytical problem. Fix: compare a newly prepared solution with the retained preparation only when the experiment is designed to test that difference; otherwise, discard aged solutions, verify visual clarity, review storage history, and check the assay's analytical controls.

Identity or nomenclature mismatch

Likely cause: a database search using a synonym or scaffold name without cross-checking the CAS number. Fix: use Reserpine, CAS No. 50-55-5, SKU N1867, molecular weight 608.27 g/mol, and the lot record together. This is particularly important when a registry uses 3,20-Yohimban-16-carboxylic acid or another naming convention.

Scope and Limitations

Reserpine N1867 is intended for research use only. It is not a diagnostic, therapeutic, or medical product, and this workflow does not establish clinical utility for hypertension or any other condition. The dossier supports use in studies related to neurotransmitter depletion, antihypertensive mechanisms, and neuropharmacology, but it does not provide a universal dose, exposure window, assay response, or stability period for every model.

Do not infer a specific mechanism, neurotransmitter response, or treatment outcome solely from the product description. Experimental conclusions should be based on the validated assay, appropriate controls, replicate design, and analytical data generated by the research laboratory. Handle the compound according to institutional chemical hygiene, waste-disposal, and biological-safety procedures, particularly because the dossier describes it as biologically potent.

Conclusion

A reproducible Reserpine workflow depends on disciplined material identification, DMSO-based dissolution planning, matched vehicle controls, fresh solution preparation, and documented storage history. The most important product-specific controls are the 608.27 g/mol molecular weight, reported purity above 98.8%, DMSO solubility with gentle warming, insolubility in water and ethanol, and solid storage at −20°C in sealed, cool, dry conditions. Applying these controls helps laboratories distinguish preparation problems from true assay behavior while keeping N1867 use within a research-only scope.